Drug Profile
Bevacizumab biosimilar - Samsung Bioepis
Alternative Names: 615; AYBINTIO; Aybintio; Onbevzi; SB-8; SP-8Latest Information Update: 14 Nov 2022
Price :
$50
*
At a glance
- Originator Samsung Bioepis
- Developer 3SBio; Organon; Samsung Bioepis
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Colorectal cancer; Fallopian tube cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
- Registered Breast cancer; Cervical cancer; Renal cell carcinoma
- No development reported Cancer